Incyte, Merck shares slide after melanoma therapy fails study

Investing


Emile Wamsteker | Bloomberg | Getty Images

Pedestrians walk across the street from a Merck & Co. facility in Summit, New Jersey

Incyte said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck‘s Keytruda failed to meet the main goal in a late-stage study.

Incyte shares fell 20 percent in premarket trading Friday, while Merck shares were down about 2 percent.

The two companies would stop the study as it did not meet the primary goal of improving progression-free survival compared to patients on Keytruda monotherapy.

Merck’s Keytruda is approved for the treating several forms of cancer, including lung cancer and advanced melanoma. The companies said the study’s second main goal of overall survival was also not expected to reach a statistical significance.

The study was evaluating a combination of Incyte’s inhibitor Epacadostat and Merck’s Keytruda for the treatment of metastatic melanoma.



Source link

Products You May Like

Articles You May Like

Watch SpaceX’s rocket land in the ocean after spinning off target
These two airline stocks are compelling buys, says strategist
FedEx is in trouble after management shake-up
Treasury yields slide amid safe haven buying, curve inversion worries
Dow futures drop nearly 200 points as sell-off looks set to continue in new week

Leave a Reply

Your email address will not be published. Required fields are marked *